RT Journal Article SR Electronic T1 A Blood-based Gene-expression Scoring System for Cancer Screening in Patients With Branch-duct Intraductal Papillary Mucinous Neoplasms JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6551 OP 6561 DO 10.21873/anticanres.14680 VO 40 IS 11 A1 REI SUZUKI A1 HIROSUMI TAMURA A1 REIKO HONMA A1 NAOKI KONNO A1 HIROKI IRIE A1 TADAYUKI TAKAGI A1 MITSURU SUGIMOTO A1 HIROYUKI ASAMA A1 YUKI SATO A1 OKUBO YOSHINORI A1 JUN NAKAMURA A1 MIKA TAKASUMI A1 TSUNETAKA KATO A1 MINAMI HASHIMOTO A1 TAKUTO HIKICHI A1 JUN-ICHI IMAI A1 SHINYA WATANABE A1 HIROMASA OHIRA YR 2020 UL http://ar.iiarjournals.org/content/40/11/6551.abstract AB Background: In patients with branch-duct intraductal papillary mucinous neoplasms (BD-IPMN), we aimed to develop a novel blood-based biomarker utilizing a gene-expression profile for the detection of pancreatic malignancies, such as IPMN-derived carcinoma (IPMC) or pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We enrolled 40 patients with pancreatic tumors (24 BD-IPMNs, four IPMCs and 12 PDACs) and identified the characteristic gene-expression profiles in pancreatic malignancies. Subsequently, we constructed a gene-expression scoring system for the proper diagnosis of pancreatic malignancies. The result was validated in 14 patients (five IPMNs, three IPMCs and six PDACs). Results: The scoring system utilizing the expression levels of 13 genes showed high diagnostic yield (sensitivity=94.0%, specificity=92.0% and area under the curve=0.94), which was confirmed in the validation set. Furthermore, its diagnostic yield was not reduced even in early-stage pancreatic malignancies (sensitivity=85.0%, specificity=93.0% and area under the curve=0.88). Conclusion: We developed a blood-based gene expression scoring system for cancer screening in patients with BD-IPMNs.